AU5543294A - Submicron emulsions as vaccine adjuvants - Google Patents

Submicron emulsions as vaccine adjuvants

Info

Publication number
AU5543294A
AU5543294A AU55432/94A AU5543294A AU5543294A AU 5543294 A AU5543294 A AU 5543294A AU 55432/94 A AU55432/94 A AU 55432/94A AU 5543294 A AU5543294 A AU 5543294A AU 5543294 A AU5543294 A AU 5543294A
Authority
AU
Australia
Prior art keywords
vaccine adjuvants
submicron emulsions
submicron
emulsions
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU55432/94A
Inventor
Shimon Amselem
Haim Aviv
Doron Friedman
George H Lowell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmos Corp
Original Assignee
Pharmos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmos Corp filed Critical Pharmos Corp
Publication of AU5543294A publication Critical patent/AU5543294A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
AU55432/94A 1993-10-29 1993-10-29 Submicron emulsions as vaccine adjuvants Abandoned AU5543294A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1993/010402 WO1995011700A1 (en) 1993-10-29 1993-10-29 Submicron emulsions as vaccine adjuvants

Publications (1)

Publication Number Publication Date
AU5543294A true AU5543294A (en) 1995-05-22

Family

ID=22237117

Family Applications (1)

Application Number Title Priority Date Filing Date
AU55432/94A Abandoned AU5543294A (en) 1993-10-29 1993-10-29 Submicron emulsions as vaccine adjuvants

Country Status (2)

Country Link
AU (1) AU5543294A (en)
WO (1) WO1995011700A1 (en)

Families Citing this family (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
US5744137A (en) * 1995-02-06 1998-04-28 The United States Of America As Represented By The Secretary Of The Agriculture Oil emulsion vaccines prepared with animal, vegetable, and synthetic oils using a mixture of nonionic surfactants
US6488933B2 (en) 1995-07-05 2002-12-03 Yeda Research And Development Co. Ltd. Preparations for the treatment of T cell mediated diseases
BR9610484A (en) * 1995-09-18 2001-09-11 Us Army Medical Res Material C Process for the production of vaccines from proteasome subunits, non-covalently complexed and multivalent
WO1997029773A1 (en) * 1996-02-13 1997-08-21 The Nisshin Oil Mills, Ltd. Vaccine-containing emulsion and vaccine-containing powder for oral administration and process for producing the same
JP2001505535A (en) * 1996-07-10 2001-04-24 インテリバックス，インコーポレイテッド Protein and peptide vaccines for inducing mucosal immunity
GB9711990D0 (en) * 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
GB9717905D0 (en) * 1997-08-22 1997-10-29 Univ Aston Lipid-containing compositions and uses thereof
AU1198599A (en) * 1997-10-24 1999-05-17 Neorx Corporation Delivery vehicles for bioactive agents and uses thereof
US6534070B1 (en) 1997-11-19 2003-03-18 Schering Aktiengesellschaft Composition with azelaic acid
IN187039B (en) 1997-12-08 2001-12-29 Council Scient Ind Res
FR2776928B1 (en) * 1998-04-03 2000-06-23 Merial Sas ADJUVATED DNA VACCINES
EP1087788A1 (en) * 1998-06-26 2001-04-04 Aventis Pasteur Mucosal targeting immunisation
EP0997734B1 (en) * 1998-10-29 2006-09-27 Council of Scientific and Industrial Research Composition useful for the early diagnosis of visceral leishmaniasis and a process for preparing the same
AU769539B2 (en) * 1999-01-29 2004-01-29 Zoetis Services Llc Adjuvants for use in vaccines
US7915238B2 (en) 1999-02-01 2011-03-29 Eisai R & D Management Co., Ltd. Immunomodulatory compounds and methods of use thereof
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
KR100711561B1 (en) * 1999-02-01 2007-04-27 에-자이가부시기가이샤 Immunological adjuvant compound
US6835721B2 (en) 1999-02-01 2004-12-28 Eisai Co., Ltd. Immunomodulatory compounds and methods of use thereof
EP1154793B1 (en) * 1999-02-26 2010-09-15 Novartis Vaccines and Diagnostics, Inc. Use of bioadhesives and adjuvants for the mucosal delivery of antigens
US6475800B1 (en) * 1999-07-22 2002-11-05 Instrumentation Metrics, Inc. Intra-serum and intra-gel for modeling human skin tissue
DE60121136T2 (en) 2000-02-15 2007-06-06 Id Biomedical Corporation Of Quebec, Ville St. Laurent Proteasome-INFLUENZA VIRUS VACCINE COMPOSITION
FR2809961B1 (en) * 2000-06-09 2004-12-03 Seppic Sa USE OF SUGAR ETHERS AS IMMUNITY ADDITIVES IN VACCINE COMPOSITIONS, THERAPEUTIC COMPOSITIONS CONTAINING THEM AND THEIR USE AS VACCINES
EP1307466B1 (en) 2000-07-31 2005-11-16 Eisai Co., Ltd. Immunological adjuvant compounds
MY134424A (en) * 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
US7314624B2 (en) * 2001-06-05 2008-01-01 The Regents Of The University Of Michigan Nanoemulsion vaccines
IL145926A0 (en) 2001-10-15 2002-07-25 Mor Research Applic Ltd Peptide epitopes of mimotopes useful in immunomodulation
RU2541809C2 (en) * 2003-04-04 2015-02-20 Зоетис Пи ЛЛК Mucrofluidic oil-in-water emulsion and vaccine compositions
WO2006100110A1 (en) 2005-03-23 2006-09-28 Glaxosmithkline Biologicals S.A. Novel composition
JP5185813B2 (en) 2005-04-26 2013-04-17 エーザイ・アール・アンド・ディー・マネジメント株式会社 Compositions and methods for cancer immunotherapy
GB2426703B (en) 2005-05-31 2007-09-19 Malvern Cosmeceutics Ltd Compositions
EP1910387B1 (en) * 2005-06-30 2016-11-16 Eisai R&D Management Co., Ltd. Compounds for preparing immunological adjuvant
NZ567979A (en) 2005-11-04 2012-02-24 Novartis Vaccines & Diagnostic Adjuvanted influenza vaccines including a cytokine-inducing agents which is an agonist of Toll-Like Receptor 7
KR20080069232A (en) 2005-11-04 2008-07-25 노바티스 백신즈 앤드 다이아그노스틱스 에스.알.엘. Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines
US10842867B2 (en) 2005-11-04 2020-11-24 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
AU2006310163B2 (en) 2005-11-04 2011-09-15 Seqirus UK Limited Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
BRPI0707300B8 (en) 2006-01-27 2021-05-25 Novartis Ag split influenza virion vaccine or purified surface antigen and method for preparing an immunogenic composition
AU2007231027B2 (en) 2006-03-24 2013-10-03 Novartis Influenza Vaccines Marburg Gmbh Storage of influenza vaccines without refrigeration
CA2647942A1 (en) 2006-03-31 2007-11-08 Novartis Ag Combined mucosal and parenteral immunization against hiv
US10138279B2 (en) 2006-04-13 2018-11-27 Regents Of The University Of Michigan Compositions and methods for Bacillus anthracis vaccination
US9839685B2 (en) 2006-04-13 2017-12-12 The Regents Of The University Of Michigan Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
EP2035035A2 (en) 2006-06-09 2009-03-18 Novartis AG Immunogenic compositions for streptococcus agalactiae
MX2009000660A (en) 2006-07-17 2009-04-08 Glaxosmithkline Biolog Sa Influenza vaccine.
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
MX2009002408A (en) 2006-09-11 2009-03-20 Novartis Ag Making influenza virus vaccines without using eggs.
EP2121011B1 (en) 2006-12-06 2014-05-21 Novartis AG Vaccines including antigen from four strains of influenza virus
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
US9452209B2 (en) 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
PT2185191E (en) 2007-06-27 2012-11-27 Novartis Ag Low-additive influenza vaccines
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
EP2200642B1 (en) 2007-10-19 2012-04-18 Novartis AG Meningococcal vaccine formulations
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
CA2718430A1 (en) 2008-03-18 2009-09-24 Novartis Ag Improvements in preparation of influenza virus vaccine antigens
WO2009143524A2 (en) 2008-05-23 2009-11-26 The Regents Of The University Of Michigan Nanoemulsion vaccines
EP2331127A2 (en) 2008-09-18 2011-06-15 Novartis AG Vaccine adjuvant combinations
CN102223876A (en) 2008-09-26 2011-10-19 纳米生物公司 Nanoemulsion therapeutic compositions and methods of using the same
EA201500910A1 (en) 2009-02-10 2016-04-29 Новартис Аг VACCINES AGAINST FLU WITH REDUCED NUMBER OF SQUALES
JP5778039B2 (en) 2009-02-10 2015-09-16 ノバルティス アーゲー Influenza vaccine regimen for epidemic strains
JP2012517416A (en) 2009-02-10 2012-08-02 ノバルティス アーゲー Influenza vaccine with increased amount of H3 antigen
JP2012519482A (en) 2009-03-06 2012-08-30 ノバルティス アーゲー Chlamydia antigen
WO2010109324A1 (en) 2009-03-24 2010-09-30 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
DK2510947T3 (en) 2009-04-14 2016-03-21 Glaxosmithkline Biolog Sa Compositions for Immunization against Staphylococcus aureus.
ES2394797T3 (en) 2009-05-21 2013-02-05 Novartis Ag Reverse genetics using non-endogenous pol l promoters
WO2010136896A1 (en) 2009-05-29 2010-12-02 Novartis Ag Assays for influenza virus hemagglutinins
EP2451833B1 (en) 2009-07-07 2018-01-17 GlaxoSmithKline Biologicals SA Conserved escherichia coli immunogens
ES2563730T3 (en) 2009-07-15 2016-03-16 Glaxosmithkline Biologicals S.A. RSV F protein compositions and manufacturing processes thereof
DK2464658T3 (en) 2009-07-16 2014-12-15 Novartis Ag Detoxified escherichia coli immunogens
WO2011012999A1 (en) 2009-07-31 2011-02-03 Novartis Ag Reverse genetics systems
WO2011030218A1 (en) 2009-09-10 2011-03-17 Novartis Ag Combination vaccines against respiratory tract diseases
GB0917002D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Improved shigella blebs
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
EP2483390A2 (en) 2009-09-30 2012-08-08 Novartis AG Expression of meningococcal fhbp polypeptides
SI2491117T1 (en) 2009-10-20 2014-03-31 Novartis Ag Improved reverse genetics methods for virus rescue
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
US9173954B2 (en) 2009-12-30 2015-11-03 Glaxosmithkline Biologicals Sa Polysaccharide immunogens conjugated to E. coli carrier proteins
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
US20130071422A1 (en) 2010-03-18 2013-03-21 Michele Pallaoro Adjuvanted vaccines for serogroup b meningococcus
US20110229516A1 (en) * 2010-03-18 2011-09-22 The Clorox Company Adjuvant phase inversion concentrated nanoemulsion compositions
HUE042330T2 (en) 2010-03-31 2019-06-28 Stabilitech Biopharma Ltd Method for preserving alum adjuvants and alum-adjuvanted vaccines
CN102892427A (en) 2010-03-31 2013-01-23 稳定性科技有限公司 Excipients for stabilising viral particles, polypeptides or biological material
ES2543795T3 (en) 2010-03-31 2015-08-21 Stabilitech Ltd. Stabilization of viral particles
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
CN103025350A (en) 2010-05-21 2013-04-03 诺华有限公司 Influenza virus reassortment method
GB201009673D0 (en) * 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
EP2585106A1 (en) 2010-06-25 2013-05-01 Novartis AG Combinations of meningococcal factor h binding proteins
GB201017519D0 (en) 2010-10-15 2010-12-01 Novartis Vaccines Inst For Global Health S R L Vaccines
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
DK2667892T3 (en) 2011-01-26 2019-05-13 Glaxosmithkline Biologicals Sa RSV vaccination program
CN103533954B (en) 2011-03-02 2015-09-09 诺华股份有限公司 Contain compared with the antigen of low dosage and/or the combined vaccine of adjuvant
HUE034673T2 (en) 2011-05-13 2018-02-28 Glaxosmithkline Biologicals Sa Pre-fusion rsv f antigens
US9149541B2 (en) 2011-07-08 2015-10-06 Novartis Ag Tyrosine ligation process
US9358284B2 (en) 2011-09-14 2016-06-07 Glaxosmithkline Biologicals Sa Methods for making saccharide-protein glycoconjugates
GB201117233D0 (en) 2011-10-05 2011-11-16 Stabilitech Ltd Stabilisation of polypeptides
WO2013057715A1 (en) 2011-10-20 2013-04-25 Novartis Ag Adjuvanted influenza b virus vaccines for pediatric priming
CA2854934A1 (en) 2011-11-07 2013-05-16 Novartis Ag Carrier molecule comprising a spr0096 and a spr2021 antigen
US20140335507A1 (en) 2011-12-12 2014-11-13 Novartis Ag Assays for influenza virus hemagglutinins
CN104023744A (en) 2011-12-23 2014-09-03 诺华股份有限公司 Stable compositions for immunising against staphylococcus aureus
EP2820126B1 (en) 2012-03-02 2017-05-17 Seqirus UK Limited Influenza virus reassortment
RU2014140521A (en) 2012-03-08 2016-04-27 Новартис Аг ADJUVANT COMPOSITIONS OF BOOSTER VACCINES
US20150161359A1 (en) 2012-06-04 2015-06-11 Novartis Ag Methods for safety testing
TR201910573T4 (en) 2012-08-31 2019-08-21 Glaxosmithkline Biologicals Sa Stabilized proteins to immunize against Staphylococcus aureus.
JP2015528456A (en) 2012-08-31 2015-09-28 ノバルティス アーゲー Stabilized protein for immunization against STAPHYLOCOCUSAUREUS
RU2015106930A (en) 2012-09-06 2016-10-20 Новартис Аг COMBINED VACCINES WITH THE MENINGOCOCC SEROGRAPH B AND K / D / S
EP4056198A3 (en) 2012-09-18 2022-12-07 GlaxoSmithKline Biologicals SA Outer membrane vesicles
EP2903650B1 (en) 2012-10-02 2018-04-04 GlaxoSmithKline Biologicals SA Nonlinear saccharide conjugates
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
JP6440619B2 (en) 2012-10-12 2018-12-19 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Uncrosslinked acellular pertussis antigen for combination vaccines
ES2826555T3 (en) 2012-11-30 2021-05-18 Glaxosmithkline Biologicals Sa Pseudomonas antigens and antigen combination
US9708585B2 (en) 2012-12-03 2017-07-18 Seqirus UK Limited Influenza virus reassortment
US20150320852A1 (en) 2012-12-18 2015-11-12 Glaxosmithkline Biologicals Sa Conjugates for protecting against diphtheria and/or tetanus
BR112015021880A2 (en) 2013-03-13 2017-09-26 Novartis Ag influenza b virus rearrangement
CN105828835A (en) 2013-05-10 2016-08-03 诺华股份有限公司 Avoiding narcolepsy risk in influenza vaccines
DE202013005100U1 (en) 2013-06-05 2013-08-26 Novartis Ag Influenza virus reassortment
DE202013005130U1 (en) 2013-06-05 2013-09-10 Novartis Ag Influenza virus reassortment
JP2016521553A (en) 2013-06-06 2016-07-25 ノバルティス アーゲー Influenza virus reassembly
EP2870974A1 (en) 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
BR112016022011A2 (en) 2014-03-26 2017-10-24 Glaxosmithkline Biologicals Sa ? mutant staphylococcal protein antigen, fusion protein, and immunogenic composition?
GB201406569D0 (en) 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
AU2016281904B2 (en) 2015-06-26 2022-08-11 Seqirus UK Limited Antigenically matched influenza vaccines
CA2990745A1 (en) 2015-07-07 2017-01-12 Seqirus UK Limited Influenza potency assays
GB2562241B (en) 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions
US20220251261A1 (en) 2019-06-21 2022-08-11 The Board Of Trustees Of The Leland Stanford Junior University Lipid nanodiscs solubilized through poly(acrylic acid-co-styrene) copolymers
GB201909680D0 (en) 2019-07-05 2019-08-21 Malvern Cosmeceutics Ltd Hypercoiling polymer derivatives
MX2022006005A (en) 2019-11-18 2022-10-27 Seqirus Pty Ltd Method for producing reassortant influenza viruses.
US11786592B2 (en) 2021-05-19 2023-10-17 The University Of Hong Kong Compositions of cardiolipin adjuvants and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3852155A (en) * 1971-09-02 1974-12-03 R Moore Cryopreservation of equine cell cultures
US4073743A (en) * 1975-04-17 1978-02-14 Merck & Co., Inc. Process for preparing an emulsion
IL74289A (en) * 1985-02-10 1989-02-28 Israel State Vaccine system comprising a live-non-virulent vaccine and an adjuvant
EP0283085B1 (en) * 1987-03-17 1992-11-11 Akzo N.V. Adjuvant mixture
CA1341245C (en) * 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
BR9106604A (en) * 1990-06-29 1993-06-22 Chiron Corp VACCINE COMPOSITION AND PROCESS TO STIMULATE AN IMMUNOLOGICAL RESPONSE IN A HOST ANIMAL

Also Published As

Publication number Publication date
WO1995011700A1 (en) 1995-05-04

Similar Documents

Publication Publication Date Title
AU5543294A (en) Submicron emulsions as vaccine adjuvants
AU2454992A (en) Dispersions
AU4878096A (en) Hepatitis b vaccine
AU6065394A (en) Mechanical morcellator
AU643259B2 (en) Micro-emulsions
AU6093296A (en) Infectious dengue 2 virus pdk-53 as quadravalent vaccine
AU3247093A (en) Flea midgut-supernatant vaccines
AU2699192A (en) Enhanced immunogenicity using leukotoxin chimeras
AU5539294A (en) Fluorocarbon emulsions
AU1588092A (en) Transmission blocking vaccine against malaria
AU5989894A (en) Live coccidiosis vaccine
AU3154395A (en) Contraceptive vaccine
AU5225896A (en) Treponema hyodysenteriae vaccine
AU7617791A (en) Recombinant immunocastration vaccine
AU2769595A (en) Contraceptive vaccine
AU5537996A (en) Hookworm vaccine
AU6820796A (en) Antigenic preparations
AU4450696A (en) Enhanced immunogenic vaccine
AU6715094A (en) Recombinant vaccine
AU3038697A (en) Meningococcal vaccine
AU3552797A (en) Vaccine preparations
AU1229492A (en) Live vaccine against colibacillosis
AU1194997A (en) Plasmid vaccine against pseudorabies virus
AU5959494A (en) Vaccines against sterols
AU4369596A (en) Sperm as vaccine vectors